有痛性糖尿病性神経障害の疫学解析と予測：2021年～2031年

主要7ヶ国における有痛性糖尿病性神経障害の総有病者数は2021年の747万2,695例から2031年には869万3,560例に増加し、年間成長率（AGR）は1.60%になると予測されます。

当レポートでは、主要7ヶ国における有痛性糖尿病性神経障害市場について調査し、疾患の背景、危険因子と合併症、2021年～2031年の市場規模予測などを提供しています。

目次

第1章 有痛性糖尿病性神経障害：エグゼクティブサマリー

第2章 疫学

• 疾患の背景
• 危険因子と合併症
• 世界的動向および実績
• 主要7ヶ国の予測調査手法
• 有病者数の疫学的予測（2021年～2031年）
• 議論

第3章 付録

List of Tables

List of Tables

• Table 1: Summary of changes to data types and countries
• Table 2: Risk factors and comorbid conditions associated with PDN
• Table 3: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

• Figure 1: 7MM, total prevalent cases of PDN, both sexes, N, ages ≥20 years, 2021 and 2031
• Figure 2: 7MM, diagnosed prevalent cases of PDN, both sexes, N, ages ≥20 years, 2021 and 2031
• Figure 3: 7MM, total prevalence of PDN (%), men and women, ages ≥20 years, 2021
• Figure 4: 7MM, diagnosed prevalence of PDN (%), men and women, ages ≥20 years, 2021
• Figure 5: Case flow map
• Figure 6: 7MM, sources used to forecast the total prevalent cases of PDN
• Figure 7: 7MM, sources used to forecast the diagnosed prevalent cases of PDN
• Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of PDN by DSPN and non-DSPN
• Figure 9: 7MM, sources used to forecast p-DPN by T1D and T2D
• Figure 10: 7MM, total prevalent cases of PDN, N, men and women, ages ≥20 years, 2021
• Figure 11: 7MM, total prevalent cases of PDN by age, N, men and women, 2021
• Figure 12: 7MM, total prevalent cases of PDN by sex, N, ages ≥20 years, 2021
• Figure 13: 7MM, diagnosed prevalent cases of PDN, N, men and women, ages ≥20 years, 2021
• Figure 14: 7MM, diagnosed prevalent cases of PDN by DSPN and non-DSPN, N, men and women, ages ≥20 years, 2021
• Figure 15: 7MM, painful diabetic peripheral neuropathy (p-DPN) among diagnosed prevalent cases of T1D and T2D, N, men and women, ages ≥20 years, 2021

Painful diabetic neuropathy (PDN) is a long-term complication of diabetes mellitus (DM). Over time, diabetic patients may develop this nerve disorder, which is the result of decreased blood flow and high blood sugar levels (Sadosky et al., 2008). Diabetic neuropathy refers to a variety of syndromes that differ in clinical course, distribution, and fiber involvement. PDN occurs in diabetic patients that develop diabetic neuropathy and experience neuropathic pain as a result of nerve damage. PDN can be interpreted as pain arising as a direct consequence of abnormalities in the somato-sensory system in diabetic patients after exclusion of other causes, based on the definition of neuropathic pain by the International Association for the Study of Pain (IASP) (Boulton, 1998; Argoff et al., 2006; Rajan, de Gray and George, 2014; Haanpaa and Hietaharju, 2015). There are different types of diabetic neuropathy, which can be grouped as peripheral, autonomic, proximal, and focal. Each type of neuropathy affects a different area of the body. Peripheral neuropathy, also known as distal symmetric neuropathy, diabetic polyneuropathy, or sensorimotor neuropathy, is the most common type of neuropathy, and affects toes, feet, legs, hands, and arms (Mayo Clinic, 2023).

In the 7MM, total prevalent cases of PDN are expected to increase from 7,472,695 cases in 2021 to 8,693,560 cases in 2031, at an annual growth rate (AGR) of 1.60%. In 2031, the US will have the highest number of total prevalent cases of PDN in the 7MM, with 2,243,421 cases, whereas Spain will have the fewest total prevalent cases of PDN with 517,322 cases. In the 7MM combined, the diagnosed prevalent cases of PDN are expected to increase from 4,447,050 cases in 2021 to 5,157,455 cases in 2031, at an AGR of 1.60%. GlobalData epidemiologists attribute the increase in the total prevalent cases and diagnosed prevalent cases of PDN to changes in the total prevalence and diagnosis rates, and population dynamics in each market.

Scope

• This report provides an overview of the risk factors, comorbidities, and global and historical trends for PDN in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for total prevalent cases of PDN (diagnosed and undiagnosed) among the diagnosed diabetic population (T1D and T2D) segmented by sex and age (in 10-year age groups beginning at age 20 years and ending at age 80 years and older) in these markets. The report also includes a 10-year epidemiology forecast for diagnosed prevalent cases of PDN (both sexes and ages 20 years and older). The diagnosed prevalent cases of PDN are further segmented by distal symmetric polyneuropathy (DSPN) and non-distal symmetric polyneuropathy (non-DSPN). This report also provides a forecast for the painful diabetic peripheral neuropathy (p-DPN) among the diabetic population (T1D and T2D). In the epidemiology model, GlobalData epidemiologists included a 10-year epidemiological forecast for total prevalent cases of diabetic neuropathy (diagnosed and undiagnosed) among the diagnosed diabetic population segmented by sex and age (beginning at age 20 years and ending at age 85 years and older) in these markets.
• The PDN epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The PDN epidemiology series will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global PDN market.
• Quantify patient populations in the global PDN market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for PDN therapeutics in each of the markets covered.
• Understand magnitude of PDN by distal symmetric polyneuropathy (DSPN) and non-distal symmetric polyneuropathy (non-DSPN).

Table of Contents

Table of Contents

1 Painful Diabetic Neuropathy: Executive Summary

• 1.1 Catalyst
• 1.2 Related reports
• 1.3 Upcoming reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities
• 2.3 Global and historical trends
• 2.4 7MM forecast methodology
  • 2.4.1 Sources
  • 2.4.2 Forecast assumptions and methods
  • 2.4.3 Total prevalent cases of PDN
  • 2.4.4 Diagnosed prevalent cases of PDN
  • 2.4.5 Diagnosed prevalent cases of PDN by DSPN and non-DSPN
  • 2.4.6 p-DPN among diagnosed prevalent cases of T1D and T2D
• 2.5 Epidemiological forecast for total prevalent cases of PDN (2021-31)
  • 2.5.1 Total prevalent cases of PDN
  • 2.5.2 Age-specific total prevalent cases of PDN
  • 2.5.3 Sex-specific total prevalent cases of PDN
  • 2.5.4 Diagnosed prevalent cases of PDN
  • 2.5.5 Diagnosed prevalent cases of PDN by DSPN and Non-DSPN
  • 2.5.6 p-DPN among diagnosed prevalent cases of T1D and T2D
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 COVID-19 impact
  • 2.6.3 Limitations of the analysis
  • 2.6.4 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 Primary Research - Prescriber Survey
• 3.3 About the Authors
  • 3.3.1 Epidemiologist
  • 3.3.2 Reviewers
  • 3.3.3 Global Director of Therapy Analysis and Epidemiology
  • 3.3.4 Global Head and EVP of Healthcare Operations and Strategy
• Contact Us